Description:

Ben Ho Park, MD, PhD
The Donna S. Hall Chair in Breast Cancer
Professor of Medicine
Interim Director, Division of Hematology/Oncology
Vanderbilt University Medical Center
Co-Leader Breast Cancer Research Program
Associate Director for Translational Research
Director of Precision Oncology
Vanderbilt-Ingram Cancer Center

Abstract:

I will be discussing how mutations in breast cancer can serve as diagnostics markers using cell-free DNA and how we can use this information to guide therapeutic decision making. I will also focus on how low frequency mutations could still serve as targets for highly effective therapies akin to lung cancers with molecular targeting of mutant EGFR, ROS1, ALK, MET, RET, HER2 etc.